S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Game-Changing News For Tesla Investors 
Microsoft Is The New Safe Haven
BREAKING: Tiny biotech successfully treats blindness (Ad)
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
BREAKING: Tiny biotech successfully treats blindness (Ad)
DOW New Hghs Coming Sooner Than Later
Why did Sarepta Therapeutics Stock Plummet?
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Game-Changing News For Tesla Investors 
Microsoft Is The New Safe Haven
BREAKING: Tiny biotech successfully treats blindness (Ad)
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
BREAKING: Tiny biotech successfully treats blindness (Ad)
DOW New Hghs Coming Sooner Than Later
Why did Sarepta Therapeutics Stock Plummet?
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Game-Changing News For Tesla Investors 
Microsoft Is The New Safe Haven
BREAKING: Tiny biotech successfully treats blindness (Ad)
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
BREAKING: Tiny biotech successfully treats blindness (Ad)
DOW New Hghs Coming Sooner Than Later
Why did Sarepta Therapeutics Stock Plummet?
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Game-Changing News For Tesla Investors 
Microsoft Is The New Safe Haven
BREAKING: Tiny biotech successfully treats blindness (Ad)
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
BREAKING: Tiny biotech successfully treats blindness (Ad)
DOW New Hghs Coming Sooner Than Later
Why did Sarepta Therapeutics Stock Plummet?
NASDAQ:HSTO

Histogen - HSTO Price Target & Analyst Ratings

$1.35
-0.06 (-4.26%)
(As of 03/21/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.29
$1.44
50-Day Range
$0.86
$1.41
52-Week Range
$0.76
$9.40
Volume
1.06 million shs
Average Volume
1.11 million shs
Market Capitalization
$5.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00

Histogen Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 1 Analyst Ratings

Consensus Analyst Price Target

$30.00
2,122.22% Upside
High Prediction$30.00
Average Prediction$30.00
Low Prediction$30.00
TypeCurrent
3/22/22 to 3/22/23
1 Month Ago
2/20/22 to 2/20/23
3 Months Ago
12/22/21 to 12/22/22
1 Year Ago
3/22/21 to 3/22/22
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$30.00$30.00$30.00$48.00
Predicted Upside2,122.22% Upside476.92% Upside476.92% Upside198.06% Upside
Get Histogen Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for HSTO and its competitors with MarketBeat's FREE daily newsletter.

HSTO Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HSTO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Histogen Stock vs. The Competition

TypeHistogenMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.64
2.47
Consensus RatingBuyBuyHold
Predicted Upside2,122.22% Upside1,902.38% Upside20.88% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/29/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$48.00 ➝ $30.00+476.92%
(Data available from 3/22/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












HSTO Price Target - Frequently Asked Questions

What is Histogen's consensus rating and price target?

According to the issued ratings of 1 analysts in the last year, the consensus rating for Histogen stock is Buy based on the current 1 buy rating for HSTO. The average twelve-month price prediction for Histogen is $30.00 with a high price target of $30.00 and a low price target of $30.00. Learn more on HSTO's analyst rating history.

Do Wall Street analysts like Histogen more than its competitors?

Analysts like Histogen more than other Medical companies. The consensus rating score for Histogen is 3.00 while the average consensus rating score for medical companies is 2.64. Learn more on how HSTO compares to other companies.

Does Histogen's stock price have much upside?

According to analysts, Histogen's stock has a predicted upside of 476.92% based on their 12-month price targets.


Stock Ratings Reports and Tools

This page (NASDAQ:HSTO) was last updated on 3/22/2023 by MarketBeat.com Staff